valproic acid has been researched along with lactulose in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alexander, CE; Omar, MI | 1 |
| Cuesta-Montero, P; Diaz-Rangel, M; Domingo-Chiva, E; Grande-Martin, A; Lopez-Perez, A; Monsalve-Naharro, JA | 1 |
| Cunningham, B; Fowler, M; Mullen, C; Nicholson, C | 1 |
2 review(s) available for valproic acid and lactulose
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug treatment for faecal incontinence in adults.
Topics: Adult; Antidiarrheals; Diarrhea; Epinephrine; Fecal Incontinence; Gastrointestinal Agents; Humans; Lactulose; Randomized Controlled Trials as Topic; Valproic Acid; Zinc Compounds | 2013 |
4 other study(ies) available for valproic acid and lactulose
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
[Valproate-induced hyperammonemic encephalopathy].
Topics: Acetamides; Anticonvulsants; Brain Diseases, Metabolic; Carnitine; Coma; Drug Therapy, Combination; Electroencephalography; Epilepsies, Partial; Female; Humans; Hyperammonemia; Lacosamide; Lactulose; Middle Aged; Models, Biological; Valproic Acid; Young Adult | 2017 |
Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients.
Topics: Carnitine; Cohort Studies; Critical Illness; Humans; Hyperammonemia; Lactulose; Retrospective Studies; Valproic Acid | 2021 |